Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Good question. I know we present on the 20th, but I'm not sure the process behind their sponsored press release. I asked my company to send me to the conference, but ticket prices were much too expensive. Guess we'll wait and see.
http://www.syracuse.com/celebrity-news/index.ssf/2016/06/charlie_sheen_condoms_safe_sex_hiv_video.html
"The father-of-five told People magazine that he tried an "AIDS" cocktail of antiretroviral drugs, as well as an alternative treatment plan in Mexico, but now is in the middle of an FDA-approved test trial of a new drug called PRO 140 from the company CytoDyn.
"It's one shot a week that they're actually moving towards having bi-monthly and then, ultimately, just once a month. But the test I'm in now is once a week, and there's no side effects," he said."
Thanks. As per the author of the marketstatsanalytics article, they view CytoDyn as potential competition. I wouldn't be surprised to see a buyout if their phase III clinical trials do well.
Any thoughts on the small biotech CytoDyn disrupting Gilead's revenue stream with their drug PRO 140 that is in clinical trials. I see Charlie Sheen is going on a PR tour saying he's doing well on the drug. I was thinking about jumping in here but I'm a little reluctant. HIV drugs account for almost half of Gileads revenue.
Thoughts on this?
http://wbt.com/how-has-being-hiv-changed-charlie-sheen/
Should see some volume today after Charlie's TV appearances yesterday.
ABC News:
http://abcnews.go.com/Entertainment/hiv-changed-charlie-sheen/story?id=39849927
Sheen is also more than half way through a 14-week Food and Drug Administration-approved test trial of a new drug called PRO 140 from the company CytoDyn.
"I'm really excited about being on the cutting edge and being a part of something I think is going to help a lot of people," he said, adding that the new drug is helping him stave off advancement of the disease with minimal side effects.
This would have been amazing exposure. I actually looked today and didn't see anything about him being rescheduled.
Does anyone else have information about Charlie going on the Today Show?
Yet another Charlie article:
http://kticradio.com/abc_health/how-having-hiv-has-changed-charlie-sheen-abcid35712947/
June 27th is national HIV testing day too. Maybe that'll increase market size/market cap.
I think that rumor originated here... I haven't found any evidence to support that Magic was in any of the trials. For that information though, it would have to come from the horses mouth. If Magic has the CCR5 tropism, it wouldn't surprise me in the least if he was in any of the trials.
Has anyone else looked in to this?
No Twitter handle, but I am sharing through other mediums. Should be a roller coaster these next 2 weeks!
Charlie talking to People magazine:
http://www.people.com/people/mobile/article/0,,21012575,00.html
Sure, a written offer....
I'm in the same boat! There are other areas I would like to diversify to, but I'm very optimistic on CYDY and see too much potential here to want to make those moves.
Clearly DoctoRX isn't familiar with CYDY in the least...who's to say that CytoDyn hasn't received an offer (probably have received a lowball offer or two (just speculating))? As retail investors we can only really speculate on those topics.
Accesswire news finally posted to the stock app for iPhone. I'll continue to post the rest of the mediums as I see them.
Thanks for that! I figured the show would be dedicated to covering the tragedy in Orlando...just couldn't find the information supporting it.
Exposure, exposure, exposure!
http://www.baystreet.ca/viewarticle.aspx?id=440927
Does anyone know if Charlie made it on the Today Show, today?
Great post there. ASM microbe conference is the largest gathering of microbiologists in the world. It's an important venue to disseminate information within the community.
It's also nice that we have an ASM sponsored press pass which will bring additional awareness of the company/drug
I completely agree. IMO, lack of exposure is one of our biggest hurdles. Monday-ASM conference we get the national/international exposure we need.
Already seeing some adding going on. Hopefully new investors/day traders realize CYDY should (IMO) be taken long and let it grow instead of trying to beat it down for daily profits. Next couple of weeks should be very exciting here!
We could definitely start to see some adding today.
IMO, we should see a bump next week with Charlie going on the Today Show. Hold on, because next week is going to be full of swings. Hopefully with new investors realizing the massive potential here, we can have a higher holding price.
Ibalizumab doesn't yet compete with PRO 140 because the phase III trial that Ibalizumab is in is for patients that have experienced treatment failure to at least 1 HIV medicine from each of the 3 main drug classes. This means that patients have to have been on HART therapy first, built resistance to those drugs, and then they can do Ibalizumab. This is a VERY tiny market in comparison to the monotherapy/combination therapy ($10+ billion market) that PRO 140 is targeting (which a patient can start immediately without having had treatment failure). Ibalizumab is in phase I for that same market as PRO 140 is in phase III for.
It really isn't a competition to PRO 140. Now if CytoDyn experiences more regulatory/trial delays, TaiMed may be able to make up SOME ground. However, it is unlikely that delays will be to the point where they TaiMed can catch CytoDyn in the phase III trials for the larger market.
I could see that scenario happening too. Hopefully enough people do their DD, realize the massive potential here, and stay long to keep it $2+.
I think an uplist to NYSE would bring in the institutions. All we need for that is a $2/share price. I see some skepticism with the ASM conference being able to drive the price up that far. But this is the largest conference for microbiologists in the world. That, coupled with receiving an ASM sponsored press release and Charlie Sheen continuing to promote PRO - you're looking at major national/global exposure. This should (IMO) bring a whole new base of investors. The science is disruptive to the current standard of care and its targeting a market that could be $10+ billion/year. I think $2+ after the conference is VERY doable.
Yet....CYDY doesn't have any institutional ownership yet. Don't be surprised of an announcement for one shortly thereafter the ASM conference.
Nah, if he was the author then the article would have complained that Dr. Nader didn't disclose his info.
Looks like Mexico picked up Charlie Sheens' story as well:
http://m.primerahora.com/entretenimiento/farandula/nota/vihlecambialavidaacharliesheen-1157480/
Some nice adding ahead of the conference tomorrow. Hopefully we continue this momentum straight to the ASM conference and new investors recognize the potential here.
I can't find the transcript, but you can listen to the call by going here and calling in to the number provided:
http://www.cytodyn.com/media/press-releases/detail/230/cytodyn-announces-investment-community-conference-call-for
Not to distract from the company, but dlcullum said he has a position in CYDY and is trying to argue for what could be opposing us. I'm taking him at face value on that, but like I said in my previous post - his negativity is overly slanted. I'll often take the same approach when debating a topic by arguing against my own viewpoint so I can see both sides.
All of that aside, I believe our major hurdles/roadblocks are (in no specific order):
-Regulatory delays
-Lack of exposure (especially for filling clinical trials)
-Bureaucracy
-Ibalizumab (because they are in a phase I, self administered clinical trial)
-CRISPR (I won't take the time to explain this because they are not even doing human trials, but they are also presenting at the ASM conference)
The science for PRO 140 is there and that is the most important part. I believe that if/when PRO 140 is approved, that it will be the new standard of care for those patients with the R5 tropism.
PRINC3ALI beat me to it - it was the news that they are presenting at a conference on June 7th for microcap companies.
Looks like there was news after all. We're going to be getting a ton of exposure over the next few weeks which hopefully equates to a lot of new investors.
As for people slamming dlcullum - he seems genuine in that he's trying to play devils advocate which is important so we can weigh the cons. With that said, ibalizumab does not (IMO) pose a threat to PRO 140's market share once PRO 140 is hopefully approved. TaiMed is in phase I for a self-administered version of their drug which is clearly behind our phase III trials.
Dlcullum - I hope people didn't push you away from the board; it's important to look at all aspects of PRO 140 and other drugs that are/could be coming to the market. However, I understand a few posters' points in that your posts seem overwhelmingly slanted towards the negative aspects.
I, personally, have a big position in CYDY and am excited to see what the coming weeks hold in store for us.
Another little pop there. I wonder if news could be on the horizon....
My guess is that the selling is tied to Paulson who did a huge private placement for CytoDyn. That's just my guess though. Outside of the 1 seller, we've had pretty good support.
The ASM Microbe Conference showcases the BEST microbial sciences in the world and is the largest gathering of microbiologists. With Bill Gates as the keynote speaker - CytoDyn's presentation was one of a few selected for an ASM-sponsored press release. With the largest HIV player (Gilead) sharing the same room as CytoDyn, CytoDyn will get the exposure it needs to attract interest from institutional investors. I personally do not expect to see a huge SP increase, but it's the next major catalyst.
Nothing unexpected in terms of volume. It's been holding nicely right around $1.00 which I believe shows that investors believe in the company's product. June 19th/20th are the next target dates for CytoDyn. Until then...
Sentiment: Hold
http://m.belfasttelegraph.co.uk/entertainment/news/charlie-sheen-feeling-amazing-due-to-hiv-drug-trial-34729694.html
Looking at international attention now.
"Charlie Sheen believes his health is dramatically improving after taking an experimental HIV drug."
http://www.tv3.ie/xpose/article/entertainment-news/203615/Charlie-Sheen-feeling-amazing-due-to-HIV-drug-trial
Just a matter of time...